Publication
Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Neoplasmcivic_curation1.00
- drugPralsetinibcivic_curation1.00
- drugSelpercatinibcivic_curation1.00
- geneRETcivic_curation1.00
- variantRET M918Tcivic_curation1.00
Curated evidence
Evidence citing this paper (11)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32284345
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RET D898_E901del2 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 4 | submitted | EID11865To assess recurrent somatic mutations in the RET kinase domain (T930K/M/P and D898_E901del) that were identified in a large study of 37,056 Chinese cancer patients, in vitro functional tests were run … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| Pralsetinib + SelpercatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID11870Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET M918T2 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 4 | accepted | EID11723Recurrent somatic mutations within or near the RET kinase domain (T930K/M/P and D898_E901del) were identified in a large study of 37,056 East Asian cancer patients. After excluding RET mutations with … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| Pralsetinib + SelpercatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID11867Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET T930K2 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11864To assess recurrent somatic mutations in the RET kinase domain (T930K/M/P and D898_E901del) that were identified in a large study of 37,056 Chinese cancer patients, in vitro functional tests were run … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| Pralsetinib + SelpercatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11869Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET T930M1 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Does Not Support Oncogenicity | 2 | submitted | EID11866To assess recurrent somatic mutations in the RET kinase domain (T930K/M/P and D898_E901del) that were identified in a large study of 37,056 Chinese cancer patients, in vitro functional tests were run … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET T930P2 | ||||||||
| (oncogenic) | Malignant NeoplasmALIAS | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11863To assess recurrent somatic mutations in the RET kinase domain (T930K/M/P and D898_E901del) that were identified in a large study of 37,056 Chinese cancer patients, in vitro functional tests were run … (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| Pralsetinib + SelpercatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11868Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET CLD1 Mutation1 | ||||||||
| (oncogenic) | Solid NeoplasmCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 1 | submitted | EID11722560 of 37,056 patients from hospitals across China were found to contain RET mutations with the prevalence highest in thyroid cancer (6.45%), mediastinal tumor (7.69%), uterine cancer (3.94%), urinary… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |
| RET TKD Mutation1 | ||||||||
| (oncogenic) | Solid NeoplasmCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 2 | submitted | EID11721560 of 37,056 patients from hospitals across China were found to contain RET mutations with the prevalence highest in thyroid cancer (6.45%), mediastinal tumor (7.69%), uterine cancer (3.94%), urinary… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC | civic |